Alkermes ALKS State US Medicaid Rebates — Accounts Payable Current

Similar metrics at other companies

MOHMedicaid — Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year

$4.72B+2.7%

MOHMedicaid — Change in non-risk and other payables

$295M+439%

CORTLong-term accrued government rebates

$4.37M—

KRYSAccrued rebates

$70.72M+49.2%

MOHMedicaid — Liability for Claims and Claims Adjustment Expense

$3.82B+7.2%

MOHMedicaid — Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid

$7.41B+0.7%

Questions, answered.

What is Alkermes's state US medicaid rebates — accounts payable current?

Alkermes (ALKS) reported state US medicaid rebates — accounts payable current of $38.6M in Q1 2026.

How has Alkermes's state US medicaid rebates — accounts payable current changed year-over-year?

Alkermes's state US medicaid rebates — accounts payable current increased by 94.0% year-over-year, from $19.9M to $38.6M.

What does state US medicaid rebates — accounts payable current mean?

This metric represents the current liability owed to state government agencies for mandatory rebates associated with the sale of pharmaceutical products under the Medicaid Drug Rebate Program. It reflects the estimated financial obligation for products dispensed to Medicaid beneficiaries that have not yet been settled with the respective state authorities. This balance is a critical indicator of the company's short-term regulatory and financial commitments within the U.S. public healthcare market.